US Broker Ratings

Amicus Therapeutics, Inc. (FOLD): Investor Outlook with a 75% Potential Upside

Amicus Therapeutics, Inc. (NASDAQ: FOLD) has positioned itself as a formidable player in the biotechnology sector, focusing on the development of novel treatments for rare diseases. With a market capitalization..

Brookdale Senior Living Inc. (BKD) Stock Analysis: Navigating Healthcare Opportunities with a 5.32% Potential Upside

Brookdale Senior Living Inc. (NYSE: BKD), a prominent player in the healthcare sector, operates an extensive network of senior living communities across the United States. Specializing in Independent Living, Assisted..

Alignment Healthcare, Inc. (ALHC) Stock Analysis: 27.44% Potential Upside Beckons Investors

Alignment Healthcare, Inc. (NASDAQ: ALHC) is making waves in the healthcare sector, particularly within the niche of Medicare Advantage plans. Based in Orange, California, this company has crafted a consumer-centric..

BGM Group Ltd. (BGM) Stock Analysis: Navigating Challenges in the Healthcare Sector

BGM Group Ltd. (BGM), a key player in China’s healthcare landscape, operates primarily within the specialty and generic drug manufacturing industry. Despite a promising market cap of $1.84 billion and..

Adaptive Biotechnologies Corpor (ADPT) Stock Analysis: Unpacking a 26.25% Potential Upside Amidst Robust Revenue Growth

Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a pioneering player in the biotechnology sector, is making waves with its groundbreaking immune medicine platform. Headquartered in Seattle, Washington, this commercial-stage company is spearheading..

Kymera Therapeutics, Inc. (KYMR) Stock Analysis: A Strong Buy with 21.69% Upside Potential

Kymera Therapeutics, Inc. (NASDAQ: KYMR) is attracting significant interest from investors and analysts alike with its innovative approach to drug development in the biotechnology sector. The company, headquartered in Watertown,..

Clover Health Investments (CLOV) Stock Analysis: Unlocking a 24.36% Upside Potential in Healthcare

Clover Health Investments, Corp. (NASDAQ: CLOV) is making waves in the healthcare sector, particularly within the healthcare plans industry. With its innovative approach to Medicare Advantage plans, Clover Health is..

Bausch Health Companies Inc. (BHC) Investor Outlook: Analyzing Growth Potential and Strategic Positioning

Investors eyeing the healthcare sector might find Bausch Health Companies Inc. (NYSE: BHC) an intriguing proposition. With a market cap of $2.37 billion, this Canadian specialty and generic drug manufacturer..

Vericel Corporation (VCEL) Investor Outlook: Analyzing a Potential 39.6% Upside in the Biotech Sector

Vericel Corporation (NASDAQ: VCEL) is capturing the attention of investors in the biotechnology sector with its promising potential upside of 39.6%, based on its recent analyst ratings. Headquartered in Cambridge,..

Janux Therapeutics, Inc. (JANX) Stock Analysis: A Biotech with a Potential 185% Upside

Janux Therapeutics, Inc. (NASDAQ: JANX) is capturing the attention of investors with its promising potential upside of 185.06%, according to recent analyst ratings. This San Diego-based biotechnology firm specializes in..

Ardent Health, Inc. (ARDT) Stock Analysis: Exploring a 39.66% Upside Potential for Savvy Investors

Ardent Health, Inc. (NASDAQ: ARDT), a prominent player in the healthcare sector, has been catching the eye of investors with its robust growth metrics and a promising potential upside. Based..

DENTSPLY SIRONA Inc. (XRAY) Stock Analysis: A 17.86% Upside Potential Amidst Mixed Financial Signals

DENTSPLY SIRONA Inc. (NASDAQ: XRAY), a prominent player in the healthcare sector specializing in medical instruments and supplies, has recently caught the attention of investors due to its notable potential..

Immunocore Holdings plc (IMCR) Stock Analysis: Exploring a Potential 79.71% Upside in the Biotechnology Sector

Immunocore Holdings plc (NASDAQ: IMCR) stands out in the biotechnology sector with a compelling growth narrative and a significant potential upside. As a commercial-stage biotechnology company, Immunocore is pioneering immunotherapies..

BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: Exploring a 174% Potential Upside

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is captivating investor interest with its substantial growth potential, as highlighted by an impressive 174% potential upside. Positioned in the healthcare sector, BioCryst specializes in..

Haemonetics Corporation (HAE) Stock Analysis: Exploring a 17.76% Potential Upside in the Medical Device Sector

Haemonetics Corporation (NYSE: HAE) stands as a prominent player in the healthcare sector, particularly within the medical devices industry. With a market capitalization of $3.3 billion, this Boston-based company has..

Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: Unveiling a 23.5% Upside Potential with Strong Buy Ratings

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is capturing investor attention in the healthcare sector, particularly within the biotechnology industry. With a market capitalization of $3.58 billion, the company stands out as..

Privia Health Group, Inc. (PRVA) Stock Analysis: Exploring a 32% Upside Potential for Investors

Privia Health Group, Inc. (NASDAQ: PRVA), a prominent player in the healthcare sector, is generating considerable buzz among investors thanks to its promising 32.42% potential upside. Specializing in health information..

Organon & Co. (OGN) Stock Analysis: Uncovering a 34% Potential Upside in the Healthcare Sector

Organon & Co. (OGN) is an intriguing player in the healthcare sector, particularly within the general drug manufacturing industry. With a market cap of $2 billion, this Jersey City-headquartered company..

Ascentage Pharma Group Internat (AAPG): Investor Outlook with 27.57% Potential Upside

Ascentage Pharma Group International (AAPG), a prominent player in the biotechnology sector, has caught the attention of investors with its significant potential upside. Headquartered in Suzhou, China, the company is..

IDEAYA Biosciences, Inc. (IDYA) Stock Analysis: Assessing a 57.82% Upside Potential for Investors

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is capturing the attention of investors with a promising 57.82% potential upside, according to analyst ratings. As a biotechnology company specializing in precision medicine oncology,..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds